

Invitation: FluoGuide presentations on strategic collaborations and FG001 commercialization

FluoGuide is advancing its position in head and neck cancer treatment. On 21 July 2025, the company announced a strategic collaboration with Olympus, a global med#tech leader. The collaboration aims to jointly develop FG001 for tumor imaging and surgical margin assessment in head and neck cancer, focusing on the clinical phase and gathering evidence on Olympus's imaging platforms.

FluoGuide now invites to two compelling presentations, where CEO Morten Albrechtsen will share insights into strategic opportunities that may accelerate the path to market - including collaborations with industry partners such as Olympus and Intuitive Surgical.

- **Thursday, 7 August 2025 - Redeye:**

A live-recorded interview with Morten Albrechtsen, CEO, conducted by Redeye analyst Christian Binder. The interview is scheduled for publication in the following days.

Questions can be submitted in advance to Christian Binder (christian.binder@redeye.se) or IR@fluoguide.com. The interview will be in English. Link to the recording will be provided on FluoGuide and Redeye websites at distribution.

- **Friday, 8 August 2025 at 15:30 - 16.30 CEST:**

A live Q&A session with Morten Albrechtsen, CEO, moderated by Thomas Petersen.

Questions can be submitted live during the event to Thomas Petersen or in advance to IR@fluoguide.com. The discussion will be in Danish.

You can subscribe to the event [here](#).

Expected takeaways from the presentations:

- **Partner strategy:** How FluoGuide selects and builds strategic partnerships to accelerate market entry and create long-term value.
- **Long-term potential:** What the partnerships mean for the commercialization of FG001 and expansion into other cancer indications.
- **Multiple partnerships:** Why FluoGuide pursue a multi-partner approach.

FluoGuide looks forward to receiving your questions and to engaging in insightful discussions during the upcoming presentations.

Follow FluoGuide on LinkedIn: <https://www.linkedin.com/company/fluoguide/>

Sign up to receive FluoGuide news: <https://fluoguide.com/investor/email-alerts/>

For further information, please contact:

Morten Albrechtsen, CEO

FluoGuide A/S

Phone: +45 24 25 62 66

E-mail: ma@fluoguide.com

About FluoGuide

FluoGuide's primary focus is to maximize surgical outcomes in oncology. FluoGuide's lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide's products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision enhances the likelihood of achieving a complete cure and helping to lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated in a proof-of-concept phase I/II clinical study in patients with high-grade glioma undergoing surgery. FluoGuide is also exploring FG001 in three other severe cancer indications: lung cancer (phase IIa), head & neck cancer (phase IIa), and both meningioma and low-grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker "FLUO".

For more information on FluoGuide's uPAR technology platform and our pipeline please visit our home page www.fluoguide.com

Attachments

Invitation: FluoGuide presentations on strategic collaborations and FG001 commercialization